AbbVie Inc. (NYSE: ABBV) is reportedly negotiating the acquisition of Gilgamesh Pharmaceuticals, a privately held mental ...

AbbVie Inc. (NYSE:ABBV) is one of the top low volatility healthcare stocks to buy now. In a report released on July 22, Vamil ...

AbbVie Inc. (NYSE:ABBV) ranks among the best low volatility stocks to buy according to analysts. Ahead of the company’s ...

AbbVie Inc. is in talks to acquire mental health therapeutics company Gilgamesh Pharmaceuticals in a deal highlighting ...

AbbVie Inc. (NYSE: ABBV) is one of the high-margin pharma stocks to buy now . AbbVie Inc. (NYSE:ABBV) received a slight boost ...

In Study 2 of the pivotal Phase 3 UP-AA clinical program, upadacitinib (RINVOQ®) achieved the primary endpoint, demonstrating that 44.6% and 54.3% of patients with ...

AbbVie Inc. (NYSE:ABBV) stands out as a major player in the pharmaceutical industry, with a broad range of approved ...

Shares of AbbVie Inc. ABBV advanced 1.22% to $187.11 Tuesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 0.06% to 6,309.62 and the ...

A Delaware federal jury said on Friday that Revance Therapeutics owes AbbVie's Allergan Inc $56 million after finding that ...

This was the stock's third consecutive day of losses.

AbbVie Inc (ABBV) is reportedly negotiating to buy Gilgamesh Pharmaceuticals, a private company focusing on mental health treatments, for roughly $1 billion. The discussions, highlighted by Bloomberg, ...

S&P Global Ratings projects Glenmark Pharmaceuticals will achieve a net cash positive position following its licensing ...